Introduction {#s1}
============

Natural products originating from diverse sources including plants, microorganisms, and marine sponges are capable to influence epigenetic modifications ([@B39]; [@B109]). Epigenetics refers to heritable changes in gene expression as well as chromatin structure without change in a DNA sequence ([@B38]). Enzymes involved in these modifications were already identified and include DNA methyltransferases, histones acetyltransferases/deacetylases, histone lysine as well as arginine methyltransferases and histone demethylases ([@B39]). The most common epigenetic modifications include DNA methylation, chromatin remodeling, histone post-translational modifications, and silencing of gene expression through non-coding RNAs ([@B5]). Epigenetic dysregulations have been shown to be involved in several diseases such as cancers, neurodegenerative, or parasitic diseases and obesity ([@B45]; [@B53]). Cancer is a disease strongly tied to epigenetic changes which lead to silencing of tumor suppressor genes and thus promote tumor formation and proliferation ([@B91]; [@B50]). Therefore, due to the reversible nature of epigenetic modifications with respect to activation or inhibition, the genes and proteins representing key epigenetic players are considered as prime targets for the treatment and prevention of cancers ([@B47]). In this review, we focus on natural products from plants, sponges, bacteria, and fungi that may serve as leads for drug discovery and possible further development for the treatment of cancers. We describe natural compounds of all biosynthetic classes inhibiting enzymes involved in the major epigenetic modifications regulating gene expression which include DNA methyltransferases (DNMTs) and histone deacetylases (HDACs). Emphasis will be on their biological properties and mode of action. Most of the natural products seem to display an indirect effect on HDACs and DNMTs and we aim to provide in this review all the data reported in the literature. It is worth to mention that currently, modifiers of DNMTs and HDACs are the only two classes of epigenetic drugs under investigation in the clinical setting.

DNA Methyltransferases Inhibitors ([**Figure 1**](#f1){ref-type="fig"}) {#s2}
=======================================================================

The transfer of methyl groups to DNA is performed by DNA methyltransferases (DNMTs). These enzymes create 5-methylcytosines (5mCs) which lead to gene repression. The development of novel drugs targeting cancer and other diseases involve DNMTs as epigenetic targets ([@B135]). DNMT1, DNMT3a, and DNMT3b were identified as the three catalytically active DNMTs in mammals. DNMT1 is described as the maintenance methyltransferase, while DNMT3a and DNMT3b are *de novo* methyltransferases ([@B9]). A crucial epigenetic modification is the modulation of the activity of DNA methyltransferases which affect DNA repair mechanisms in the cells or gene expression. The pathogenesis of human cancer is partly due to aberrant modiﬁcations in the activity of DNMTs ([@B89]). DNMTs modulate DNA methylation and in general perform methylation of nitrogen (*N*-methylation), oxygen (*O*-methylation), and carbon (*C*-methylation). Those events are universal processes critical to all organisms. The *O*-methylation patterns of polyhydroxylated small molecules in plants, are essential using the same or similar intermediates and substrates to generate final product distribution through multiple branched biosynthetic pathways ([@B156]; [@B254]). In any organism, methylation is essential in the management of normal biological activities ([@B49]). Methylation can cause direct suppression of gene expression even though it is an heritable change in the DNA without a modification of the sequence ([@B37]). Hypomethylation and hypermethylation of DNA are seen in cancer cells ([@B168]). The expression of pro-metastatic genes and quiescent proto-oncogenes is assisted by hypomethylation, and thus increase the progression of tumors. Silencing of genes influencing important cellular signaling pathways can be due to hypermethylation of the promoter regions of tumor-suppressor genes which play an important role in neoplastic transformation of cells ([@B168]).

![Structures of DNA methyltransferases inhibitors.](fphar-11-00992-g001){#f1}

There are few drugs targeting DNA methyltransferase as inhibitors (DNMTIs), such as azacytidine and decitabine which are the most outstanding epigenetic drugs extensively utilized as epigenetic modulators. However, their application for oncological diseases is restricted by their relative toxicity and poor chemical stability ([@B66]). Promising results in cancer treatment *via* influencing DNA methylation are expected from natural products isolated from plant, animals, and microorganisms. Indeed, bioactive phytochemicals that are widely available and exhibit less systemic toxicity have shown signiﬁcant anticancer properties. The potential utilization of natural products in cancer chemoprevention and/or therapy and their plausible role as epigenetic modulators have been diligently evaluated ([@B223]). Moreover, diverse epigenetic modifications such as DNA methylation patterns including the global hypomethylation of oncogenes and the hypermethylation of tumor-suppressor genes are influenced by natural products from diverse origins. Nature is thus, a promising source of DNMTIs that may be useful in the treatment of cancer ([**Table 1**](#T1){ref-type="table"}). However, confirmation of the potential advantageous epigenetic effects after extended utilization in humans is highly dependent on successful delivery to allow for effective concentrations at the target cells and requires well-controlled clinical studies ([@B89]). Moreover, most of the natural products target all DNMT isoforms leading to a low specificity that might limit their potential use in clinical development.

###### 

Selected DNMT inhibitors.

  Compound name                    IC~50~ Values   DNMTIsoforms   Reference
  -------------------------------- --------------- -------------- -----------
  (-)-epigallocatechin-3-gallate   0.47 µM         DNMT1          [@B112]
  Curcumin                         0.30 µM         DNMT1          [@B105]
  Kazinol Q                        7.00 µM         DNMT1          [@B236]
  Nanaomycin A                     0.50 µM         DNMT3b         [@B104]
  Parthenolide                     3.50 µM         DNMT1          [@B121]
  Antroquinonol D                  5.00 µM         DNMT1          [@B231]

(--)-Epigallocatechin-3-gallate {#s2_1}
-------------------------------

Green tea contains (--)-epigallocatechin-3-gallate (EGCG) (**1**) [**Figure 1**](#f1){ref-type="fig"}) as the profuse catechin ([@B20]). Green tea is a popular natural beverage worldwide known to possess cancer preventive activities due to the presence of polyphenols such as catechins ([@B239]). EGCG and green tea polyphenols have demonstrated interesting chemopreventive effects and probable cancer chemotherapeutic effects against diverse cancers including liver, stomach, breast, lung, and skin ([@B154]; [@B251]; [@B97]). EGCG was first reported in 2003 to inhibit DNMT activity with an IC~50~ value of 20 µM and reactivate methylation-silenced genes in cancer cells ([@B52]). The same study showed that EGCG non-covalently binds to the DNMT1 catalytic active site. Another study reported that EGCG was a more potent inhibitor of DNA methyltransferase, compared to other polyphenols, with IC~50~ values between 0.21 and 0.47 µM in a direct inhibition assay ([@B112]). The authors demonstrated that the inhibitory interaction with the catalytic site of human DNMT1, and the high-affinity is due to the gallic acid moiety of EGCG ([@B112]). Moreover, its binding with the enzyme is stabilized by Mg^2+^ ([@B112]). Hussain and co-workers reported that EGCG inhibits the growth of HeLa cancer cells in a dose- and time-dependent manner through the induction of apoptosis ([@B187]). Later on, it was found that EGCG inhibits DNA methyltransferases in HeLa cells in a time-dependent manner by reversal expression of diverse tumor-suppressor genes ([@B98]). Indeed, treatment of HeLa cells with EGCG, displayed a reduced expression of DNMT3b and docking studies indicated a direct binding of EGCG in the substrate-binding pocket of this enzyme. Another study also highlighted the potential of EGCG to inhibit DNMT in a breast cancer cell line ([@B136]). However, Medina-Franco and co-workers contradicted the previous results suggesting a negligible inhibitory activity of (−)-epigallocathechin-3-gallate (EGCG) and curcumin ([@B134]).

Curcumin {#s2_2}
--------

The polyphenol curcumin (**2**) has been isolated from *Curcuma longa* and is a major yellow pigment extracted from the popular Indian spice turmeric ([@B162]; [@B201]). It has been reported in the treatment of skin wounds, certain tumors, as well as inflammation ([@B125]). However, curcumin is known as a PAINS (pan-assay interference compounds) and thus its bioactivities have to be analyzed with care ([@B152]). A recent report indicated an inhibition of the growth of myeloma cells by curcumin with an IC~50~ value of 10 µM ([@B27]). Curcumin has been reported to induce cell cycle arrest at G1/S phase in androgen-sensitive prostate cancer LNCaP cells and androgen insensitive PC-3 cells ([@B206]). Curcumin was reported to covalently block the catalytic thiolate of DNMT1 with an IC~50~ value of 30 nM after 72 h of treatment and leading to an inhibitory effect on DNA methylation ([@B122]). [@B244], showed a down-regulation in DNMT1 expression caused by curcumin in acute myeloid leukemia (AML) cell lines, both *in vitro* and *in vivo* ([@B244]). The same study highlighted reduction in the expression of positive regulators of DNMT1, Sp1 and p65 by curcumin. In AML cell lines, the latter results correlated with a decrease in binding of these transcription factors to the DNMT1 promoter. Curcumin displayed an inhibitory effect on DNMT in three colorectal cells lines including CT116, HT29 and RKO ([@B120]). The DNA methylation changes in the same study occurred only in a subset of primarily partially methylated genes, and in a time-dependent manner. As mentioned earlier, the DNMT inhibition activity of curcumin has also been questioned ([@B134]).

Quercetin {#s2_3}
---------

Quercetin (**3**), an ubiquitous dietary flavonoid, is commonly found in fruits, vegetables, and beverages. It has attracted considerable attention owing to its potent antioxidant and antiproliferative activities. The induction of apoptosis and cell cycle arrest by quercetin in several cancer cell lines among which breast carcinoma, human esophageal squamous cell carcinoma, and prostate cancer cell lines has been demonstrated ([@B147]; [@B90]; [@B246]). Recently, it was reported that the pro-apoptotic effect of quercetin was mediated by inhibition of DNMT, especially DNMT1 and DNMT3a *in vitro* and human xenograft models ([@B6]). Another study displayed a concentration-dependent effect on hypermethylation of the tumor suppressor gene, p16^INK4a^ when the human colon carcinoma RKO cells were treated by quercetin ([@B214]). This led to the reversal of the abnormal hypermethylation status of this gene after 120 h exposure to quercetin. Quercetin is currently undergoing phase I clinical trials in combination with green tea extracts ([@B255]). However, in the last update at ClinicalTrial.gov, the status is "recruiting" and no results have been published yet. Furthermore, it was reported that quercetin could be used in the treatment of diseases such as diabetes, in which its methylglyoxal (MGO) adduct plays an important function ([@B224]).

Kazinol Q {#s2_4}
---------

Kazinol Q (**4**) is a natural flavan isolated from the root of *Broussonetia kazinoki* which suppressed the proliferation of MCF‐7 breast and LNCaP prostate cancer cells, due to its capability to induce ROS-dependent cell death in gastric cells ([@B233]). Later on, it was shown that kazinol Q inhibits the growth of MCF‐7 breast and LNCaP prostate cancer cells, in part, through apoptosis induction ([@B236]). The antiproliferative activity of kazinol Q was found to be due at least in part to its inhibition of DNMT1 with an IC~50~ value of 7 µM ([@B236]). It is worth to mention that kazinol Q was the only active compound among the 12 isolated from formasan plants and used in this study.

Resveratrol {#s2_5}
-----------

Resveratrol (3, 4′, 5-trihydroxystilbene) (**5**) is a naturally occurring phytoalexin presents in grapes, berries, soy beans, pomegranate and peanuts, produced by spermatophytes, in response to an injury ([@B198]). The source of resveratrol in the human diet is red wine ([@B21]). This compound has been shown to inhibit cancer initiation, promotion, and progression ([@B88]). Resveratrol has been reported to inhibit the activity of DNMT3b and DNMT1 in mammary tumors in a dose-dependent fashion ([@B169]; [@B170]). The combination of resveratrol with pterostilbene, another stilbene found in the plant, revealed a decrease of the activity of DNMT3b in HCC1806 triple-negative cancer cells without affecting the control MCF10A breast epithelial cell line ([@B93]). Another study showed that resveratrol can down-regulate the activity of DNMTs, as well as other proteins including HDAC1 and MeCP2 in MDA-MB-231 and MCF7 breast cancer cell lines ([@B140]). However, the positive effects of resveratrol have been largely demonstrated *in vitro* or animals studies, with only limited effects reported in clinical studies ([@B191]). Furthermore, a lower DNMT inhibition of resveratrol has been observed when compared to other dietary bioactive compounds such as EGCG.

Nanaomycin A {#s2_6}
------------

Nanaomycin A (**6**) is a quinone isolated from *Streptomyces rosa* var. *notoensis* and first reported as an antibiotic ([@B215]). The treatment of three different human tumor cell lines including HCT116 (colon), A549 (lung), and HL60 (bone marrow) cells with nanaomycin A resulted in growth inhibition of all three cell lines and caused induction of apoptosis ([@B104]). Furthermore, an enzymatic assay revealed that the antiproliferative activity of nanaomycin A was due to its specific inhibition of DNMT3b with an IC~50~ value of 500 nM. This result was confirmed further by docking studies, which established the non-covalent binding of nanaomycin A to the active site of DNMT3b (see *Molecular Modeling and Docking as a Tool for a Mode of Action Prediction of Natural Product DNMTs and HDACs Inhibitors*) ([@B104]). Furthermore, Nakamae and co-workers, recently suggested that, DNMT3b inhibition by nanaomycin A can promote the hepatoblast differentiation ([@B148]). The later result should assist in the future generation of functional hepatocyte-like cells for pharmaceutical research. Moreover, the induction of genomic demethylation is caused by nanaomycin A which is the first selective inhibitor of DNMT3b ([@B22]). It has been hypothesized that the inhibition arises from the nucleophilic attack of the catalytic cysteine residue within the active site of DNMT to the α,β-unsaturated carbonyl of nanaomycin A ([@B22]). While the further characterization is needed, the reactivity of the Michael acceptor moiety and toxicity of nanaomycin A may lead to challenges in such characterization in the future.

Genistein {#s2_7}
---------

Genistein (**7**) is an isoflavone originally isolated from the dyer´s broom *Genista tinctoria* ([@B142]). It was reported to be a potent inhibitor of cell proliferation on pancreatic cancer cell lines through apoptosis induction, regulation of the signal transducer and activator of transcription 3 (STAT3) signaling pathway, and G~0~/G~1~ cell cycle arrest ([@B16]). Ralhan and co-workers showed that genistein is able to induce a significant decrease in the transcript levels of all the DNMTs including DNMT1, DNMT3a, and DNMT3b, in breast cancer ([@B140]). Another study confirmed this antiproliferative activity on the human breast cancers lines MCF-7 and MDA-MB-231 ([@B238]). The latter activity was found to be due to the inhibition of DNMT1 and molecular modeling indicated the direct interaction of genistein with the catalytic domain of this enzyme ([@B238]). However, only 40% inhibition of DNMT activity was observed at 100 mM contradicting the modeling data and thus indicating a low potential of genistein for DNMT inhibition. This weak effect suggests an indirect pathway of inhibition of DNA methylation, based on the identification of multiple targets for genistein including HDAC, tyrosine specific protein kinase, topoisomerase I and II, and NF-kB ([@B4]; [@B157]; [@B116]; [@B210]). Despite the preclinical data reported for genistein showing its remarkable efficacy against prostate cancer *in vitro* with diverse molecular targets, there is no convincing clinical proof or evidence that genistein might be useful in prostate cancer therapy. Moreover, genistein is a multi-target compound limiting, therefore, its potential clinical use ([@B126]; [@B160]).

Sulforaphane {#s2_8}
------------

The isothiocyanate sulforaphane (SFN) (**8**) is found in cruciferous vegetables, such as broccoli sprouts and broccoli ([@B51]). The strong inhibition of the growth of the human breast cancer cells lines MCF-7, MDA-MB-231, and SK-BR-3 by sulforaphane with IC~50~ values of 14.05, 19.35, and 16.64 µM respectively has been reported. Inhibition of cell growth was accompanied by cell cycle arrest, elevation in the levels of the tumor suppressors p21 and p27 and cellular senescence as well as induction of apoptosis. The anticancer effects of sulforaphane were found to be mediated by a global DNA hypomethylation, decreased levels of DNMT1 and DNMT3b and changes in the microRNA profiles of the three breast cancer cells lines ([@B115]). A further study showed that combination of sulforaphane and withaferin A, another natural compound, significantly causes down-regulation of overexpressed DNMT3a, DNMT3b, and HDAC1 and breast cancer cell death ([@B179]). Recently, it has been demonstrated that sulforaphane can suppress the growth of NPC cells via the inhibition of DNMT1 and the restoration of the expression of Wnt inhibitory factor 1 (WIF1) ([@B28]). Na and co-workers reported that sulforaphane up-regulates NrF2 expression and promotes its nuclear translocation through decreasing levels of DNA methylation of the Nrf2 promoter in a cellular model of Alzheimer\'s disease ([@B250]). Furthermore, sulforaphane was shown to exert its chemopreventive effect in lung cancer A549 cells partly through the down-regulation of the activity of DNMT3a ([@B60]). Reduction of the toxicity of the chemotherapeutic drug cadmium selenide by sulforaphane in human hepatocytes through induction of glutathione synthesis was shown, thereby protecting the liver against toxicity and allowing the use of higher doses ([@B232]). However, there is no proof that a higher concentration could be achieved clinically using either diet-derived or supplemented SFN. The use of phytochemicals including SFN for patients with diagnosed cancers still need deep studies whether or not the patient is undergoing chemotherapy ([@B80]). Furthermore, the presence of a highly electrophilic chemical functionality will probably cause several off-target effects despite that the downstream epigenetic effects observed upon the use of sulforaphane are promising and may improve chemopreventive activity ([@B30]).

Boswellic Acids {#s2_9}
---------------

Boswellic acids (BA) (**9**) are pentacyclic terpenoids extracted from *Boswellia serrata*; a plant used traditionally to treat inflammatory diseases ([@B253]). Inhibition of cell proliferation and apoptosis induction in colorectal cancer (CRC) cell line through up-regulation of miR-34a and down-regulation of miR-27a by the most active boswellic acid, acetyl-11-keto-β-boswellic acid (AKBA), is well established ([@B213]; [@B219]). AKBA induces demethylation and concurrent up-regulation of tumor suppressor genes including SAMD14 and SMPD3 in CRC cells ([@B189]). Moreover, AKBA was reported inhibiting DNMT in SW48 and SW480 CRC cell lines at a concentration of 40 µM. BA has been established as a multitargeting agent involved in the treatment of diverse chronic diseases including cancers ([@B178]). Indeed, modulation by boswellic acids of diverse molecular targets, such as kinases, enzymes, growth factors, receptors, transcription factors, and others related to the proliferation and survival of cells is possible ([@B177]). However, the possible development of boswellic acids as an effective drug has been tumbled down due to concerns regarding the pharmacokinetic properties.

Z-Ligustilide {#s2_10}
-------------

Z-ligustilide (**10**) is the most potent bioactive component found in *Angelica sinensis*, a herb from traditional Chinese medicine (TCM) used in the treatment of breast cancer ([@B124]). This compound has been reported to induce apoptotic cell death in human ovarian cancer cells ([@B108]). Z-ligustilide was reported to inhibit the growth of murine prostate cancer TRAMP C1 cells. The same study showed that Z-ligustilide reduced the methylation level of the first five CpGs of the NrF2 promoter. An enzymatic assay showed that Z-ligustilide blocks DNA methyltransferase activity of the CpG methylase M.SssI *in vitro* ([@B209]). The latter is structurally significantly similar to the DNMT. This result suggests that Z-ligustilide acts through an indirect mechanism of DNA methylation inhibition limiting its potential use in clinical trials.

Parthenolide {#s2_11}
------------

Parthenolide (**11**) is a germacrane sesquiterpene lactone isolated from the plant *Tanacetum parthenium* ([@B57]). This plant is commonly used for its inflammatory properties and suggested to be used in epigenetic cancer therapy ([@B3]; [@B63]). Parthenolide inhibits the detyrosination of microtubules and accelerates neuronal growth ([@B57]). A recent report showed that parthenolide induces apoptosis and inhibits proliferation of human 786-O kidney cancer cells *in vitro* ([@B42]). The compound is also known to induce apoptosis in primary acute myeloid leukemia (AML) cells, including the stem and progenitor cell compartment through inhibition of NF-kB and HSP70 ([@B161]). Parthenolide has been reported to inhibit DNMT1 with an IC~50~ value of 3.5 µM. This inhibition is thought to be due to its gamma methylene lactone which probably alkylates the proximal thiolate of Cys^1226^ of the catalytic domain ([@B121]). Recently, a new parthenolide derivative, dimethylamino-parthenolide, has been reported to inhibit the Nuclear chain factor kappa‐light‐chain enhancer of activated B cells (NF-κB) pathway and causes depletion of glutathione levels; the latter causing cancer cells to be more susceptible to oxidative stress‐induced cell death ([@B161]; [@B107]). This result highlights the potential role of this drug as a chemopreventive agent and in epigenetic cancer therapy. Recently, it has been demonstrated that combination of the anticancer drug actinomycin-D, which functions by intercalating into DNA, and dimethylamino-parthenolide results in a synergistic inhibition of Panc‐1 pancreatic cancer cell growth ([@B107]). However, the potential clinical use of parthenolide is still not clear. Indeed, analysis of parthenolide activity at Cancer Research Technologies, using a fluorescence intensity assay for DNMT1 did not find DNMT1 activity ([@B30]). Moreover, the presence of several off-target effects complicates the analysis of cell-based assays.

Antroquinonol D {#s2_12}
---------------

Antroquinonol D (**12**) is an ubiquinone derivative isolated from the mycelium of *Antrodia camphorata* ([@B231]). This compound inhibited the growth of MCF7, T47D, and MDA-MB-231 breast cancer cells without harming normal MCF10A and IMR-90 31 cells with IC~50~ values of 8.01, 3.57, and 25.08 μM respectively ([@B231]). The authors reported that antroquinonol D can inhibit the activity of DNMT1 in MDA-MB-231 breast cancer cells with an IC~50~ value lower than 5 µM. This result was confirmed by molecular modeling which revealed that antroquinonol D binds to the catalytic subunit of DNMT1 and competes for the same binding pocket in the DNMT1 enzyme as the cofactor SAM (S-adenosylmethionin) ([@B231]). Antroquinonol D was also found to reverse the silencing of multiple tumor suppressor genes in the same study.

HDAC Inhibitors {#s3}
===============

Histone deacetylases (HDACs) also called lysine deacetylases (KDAC) are a family of hydrolases catalyzing removal of acetyl groups from lysine residues on histone tails ([@B65]). This removal of acetyl groups allows compacted chromatin to reform and this process is associated with transcriptional repression ([@B65]). HDACs are classified in four distinct subtypes: class I (HDACs 1, 2, 3, and 8 localized in the nucleus), class II (IIa: HDACs 4, 5, 7, and 9; IIb: HDACs 6 and 10, found in both nucleus and cytoplasm), class III (nicotinamide adenine dinucleotide-dependent SIRT \[sirtuin\] enzymes \[Sirt 1--7\]), and class IV (HDAC 11). The later shares structural similarities with both class I and II HDACs as they are Zn-dependent enzymes ([@B70]; [@B131]). Class I HDACs play an important role in cell survival and proliferation, while class II may have tissue-specific roles ([@B118]). It has been reported that functional dysregulation of HDACs affects the expression of numerous genes that have an impact on apoptosis and the cell cycle ([@B74]). Indeed, HDAC1 is overexpressed in prostate cancer cells, while gastric carcinomas, colorectal carcinomas, and cervical dysplasias overexpress HDAC2 ([@B71]; [@B82]; [@B203]).

HDAC inhibitors (HDACi) are emerging therapeutic agents, since their targets play an important role in cancer initiation and progression ([@B114]). Indeed, histone deacetylation plays a key role in tumor suppressor genes silencing (TGSs) in several cancers, thus the restoration of the acetylation of lysine residues by HDAC inhibitors will oppose the frequent HDAC overexpression in cancer ([@B163]). HDACs are also known to regulate non-histone proteins involved in cancer development such as p53, and NF-kB and can affect their function leading to modified expression of cancer-related genes ([@B183]; [@B237]). HDACs can repress the expression of receptors for growth-restraining signaling molecules such as TGFβ receptor (transforming growth factor beta receptor), leading to unhindered cell growth, which is preventable by HDAC inhibition ([@B65]).

The well-known effect of HDACi is to lead to cell cycle arrest and induction of cell senescence ([@B67]). Since the approval of suberanilohydroxamic acid (SAHA) by the US Food and Drug Administration for the treatment of T-cell lymphoma in 2006, the relevance of HDACi in cancer therapy has been strongly pointed out. HDACi are usually classified in two main groups: group I which displays the zinc-binding mode of action includes linear inhibitors, cyclic tetrapeptides, and cyclic depsipeptides; and group II with a non-zinc-binding mode of action includes miscellaneous inhibitors ([@B109]). It is worth mentioning that most HDACi share the same overall structure including a cap terminus, a linker region, and a zinc-binding group (ZBG) ([**Figure 2**](#f2){ref-type="fig"}). As shown in [**Table 2**](#T2){ref-type="table"}, nature is a promising source of HDACi that may inspire the development of lead structures for the potential treatment of cancer. However, the lack of HDAC isoform selectivity for most of the natural products may limit their clinical use.

![Common features of HDAC inhibitors.](fphar-11-00992-g002){#f2}

###### 

Selected HDAC inhibitors.

  Compound name                 IC~50~ Values   HDAC Isoforms   Reference
  ----------------------------- --------------- --------------- -----------
  Trichostatin A                0.08 µM         NT              [@B155]
  Depudecin                     4.70 µM         HDAC1           [@B105]
  Psammaplin A                  0.042 µM        HDAC1           [@B12]
  Sulforaphane                  36.00 µM        HDAC2           [@B31]
  0.60 µM                       HDAC9                           
  Bis(4-hydroxybenzyl)sulfide   1.43 µM         NT              [@B202]
  Azumamide E                   0.05 µM         HDAC1           [@B129]
  0.10 µM                       HDAC2                           
  0.08 µM                       HDAC3                           
  Apicidin                      0.001 µM        NT              [@B197]
  Apicidin A                    0.001 µM        NT              
  Apicidin D~1~                 0.004 µM        NT              
  Apicidin B                    0.01 µM         NT              [@B196]
  Apicidin C                    0.006 µM        NT              
  FR235222                      0.017 µM        NT              [@B182]
  AS1387392                     0.022 µM        NT              
  Chlamydocin                   0.00015 µM      HDAC1           [@B58]
  1-alaninechlamydocin          0.0064 µM       NT              [@B44]
  Trapoxin A                    0.00082 µM      HDAC1           [@B58]
  0.524 µM                      HDAC6                           
  Microsporin A                 0.55 µM         HDAC8           [@B68]
  Romidepsin                    0.036 µM        HDAC1           [@B59]
  0.047 µM                      HDAC2                           
  0.510 µM                      HDAC4                           
  Largazole                     0.0114 µM       HDAC1           [@B205]
  3.0 µM                        HDAC4                           
  Epicocconigrone A             4.6 µM          HDAC6           [@B46]
  1.6 µM                        HDAC8                           
  8.4 µM                        HDAC10                          

NT, Not Tested.

Zinc-Binding Inhibitors {#s3_1}
-----------------------

### Linear HDAC Inhibitors ([**Figure 3**](#f3){ref-type="fig"}) {#s3_1_1}

#### Trichostatin A {#s3_1_1_1}

Trichostatin A (TSA) (**13**) is the first natural product derived HDAC inhibitor and was isolated from the bacterium *Streptomyces hygroscopicus* ([@B221]; [@B242]). Its structure consists of an aromatic group, a conjugated diene linker region, and a hydroxamic tail. The first racemic synthesis of TSA was reported by Krebs and co-workers in 1983 and this compound was first reported to display antifungal activity ([@B221]; [@B55]). Trichostatin A was reported to reversibly inhibit mammalian HDAC and accordingly was found to induce accumulation of acetylated histones in a variety of mammalian cell lines when applied in nanomolar concentration ([@B242]; [@B243]). The crystal structure showed that trichostatin A non-covalently binds to the active site of HDACs through the terminal hydroxamic acid group which chelates the Zn^2+^ in a bidendate fashion (see *Natural Product HDAC Inhibitor in the PDB*) ([@B54]). Kinetic studies revealed that trichostatin A is a competitive inhibitor ([@B185]). Yokoyama and co-workers reported that trichostatin A inhibits HDAC in a dose-dependent manner in vascular smooth muscle cells (VSMCs) with an IC~50~ value of 0.08 µM ([@B155]). Trichostatin A is frequently used as a positive control and a reference when compared to other HDAC inhibitors and considered today as one of the most potent HDAC inhibitors ([@B240]; [@B14]). However, the observed mutagenicity of the hydroxamic moiety along with lack of HDAC isoform selectivity limits its clinical use ([@B96]; [@B188]).

![Structures of linear HDAC inhibitors. The colors are representative of different parts shown in [**Figure 2**](#f2){ref-type="fig"}.](fphar-11-00992-g003){#f3}

#### Depudecin {#s3_1_1_2}

Depudecin (**14**) is a linear polyketide containing two epoxide groups isolated from the culture broth of the soil fungus *Alternaria brassiccicola* ([@B128]). The structure of depudecin consists of a bis-*trans*-epoxide moiety and six asymmetric centers. Depudecin has been reported to display an *in vitro* inhibitory effect against HDAC1 in a dose-dependent manner with an IC~50~ value of 4.7 µM ([@B105]). The relatively low potency of depudecin precluded further work on this compound. Depudecin showed also the ability to induce morphological reversion in NIH 3T3 fibroblast cells to their normal flat phenotype ([@B105]).

#### Psammaplin A {#s3_1_1_3}

Psammaplin A (PsA) (**15**) is a monobrominated tyrosine derived oxime containing cystamine isolated from several marine sponges including *Psammaplysilla* sp. ([@B171]; [@B212]). Psammaplin A is one of the members of the psammaplin class and was reported to suppress carcinogenic properties of several human cancer cell lines including lung, breast, colon, and ovarian cancer *in vitro* ([@B159]). Psammaplin A inhibited *in vivo* tumor growth in the A549 lung xenograph mouse model while maintaining low toxicity ([@B164]). Moreover, psammaplin A was reported to inhibit the activity of HDAC and DNMT at nanomolar levels *in vitro* ([@B164]). Hyperacetylation of histone H3 by psammaplin A demonstrated that the compound is a specific and potent inhibitor of class I HDAC rather than class II ([@B102]). Moreover, psammaplin A was found to be a natural prodrug. Its activation is caused by reduction of the disulfide bond leading to a thiol. The latter thiol chelates the Zn^2+^ ion in the active site of HDAC and precludes access to the natural substrate ([@B102]). Indeed, the reduced form of psammaplin A highly selectively inhibited HDAC1 with an IC~50~ value of 45 nM ([@B12]). The hyperacetylation of histone by psammaplin A was correlated with an up-regulation of tumor suppressors such as p21^WAFI^ and gelsolin ([@B102]; [@B1]). Psammaplin A was also reported to induce an increase of apoptosis, most likely by inducing expression of p21^WAF1^. It is worth to mention that the physiologic instability of the psammaplin class has precluded further clinical investigations. However, an analogue of psammaplin class, NVP-LAQ824, which induces apoptosis, has entered phase I clinical trials ([@B175]; [@B35]).

#### Diallyl Disulfide (DADS) {#s3_1_1_4}

Diallyl disulfide compounds are organosulfur compounds (OSC) which are released by plants of the *Allium* genus including onion, garlic, scallion, and leek ([@B11]). In general, organosulfur compounds are known to modulate the activity of several enzymes involved in the activation or detoxification of carcinogens and inhibit the formation of DNA adducts in diverse target tissues ([@B158]). DADS are known to induce cell cycle arrest, differentiation, and apoptosis in several cancer cell lines ([@B75]). In fact, DADS belong to the group of dietary HDAC inhibitors. Allyl mercaptan (**16**), a well-known DADS, induced histone acetylation in the liver and this compound was also recognized as the active HDAC inhibitor rather than the parent compound DADS ([@B43]). Indeed, the authors reported that allyl mercaptan inhibits 92% of HDAC activity while the parent compound, inhibited only 29% at the concentration of 200 µM. DADS is also known to induce the hyperacetylation of histone H4, the activation of caspase-3, and the modulation of the anti-apoptotic paralogues including Bcl2, BAX ,and Bcl-xL in human leukemia, lung cancer, and breast cancer ([@B75]; [@B249]). The latter result suggested that the Bcl-2 family is targeted by DADS. Besides, DADS was reported to cause hyperacetylation of H3 and H4 leading to an increase of the expression of the tumor suppressor p21^WAFI^ in human acute myeloid leukemia HL-60 cells and colon cancer cells *in vitro* and *in vivo*.

*S*-allyl-mercapto-*L*-cysteine (SAMC) (**17**) is another organosulfur compound which was also reported to induce hyperacetylation of H3 and H4 in human colon and breast cancer cells ([@B110]). The same study reported that SAMC inhibits cell proliferation of DS19 mouse erythroleukemia cells with an IC~50~ value of 0.5 µM ([@B110]). SAMC has also been reported to inhibit the growth of the breast cancer cell lines MCF-7 and MDA-MB-231 through cell cycle arrest in the G~0~/G~1~ phase ([@B248]). These findings support the continue investigation of SAMC as an alternative agent in the chemoprevention and chemotherapy of human breast cancer. Despite the lack of direct inhibition of HDAC by SAMC, it can be assumed that this compound displays this activity with the same mechanism as other organosulfur compounds. However, the stability of DADS causes difficulties in reproducibility of findings.

#### Sulforaphane (SFN) {#s3_1_1_5}

The isothiocyanate sulforaphane (SFN) (**8**), as mentioned earlier, is found in cruciferous vegetables, including broccoli sprouts and broccoli ([@B51]). Isothiocyanates result from the hydrolysis of glucoraphanin by the plant enzymes myrosinases ([@B100]). Isothiocyanates are a family of compounds including sulforaphane, allyl isothiocyanate, benzyl isothiocyanate, phenetyl isothiocyanate, etc. ([@B100]). Sulforaphanes have been reported to possess anticancer activities in xenograft models of prostate cancer and in induced animal models ([@B245]; [@B51]). Myzak and co-workers reported that sulforaphane possesses anticancer activity through the inhibition of HDAC activity and increase in the histone acetylation in HCT116 human colorectal cancer cells ([@B145]). The same study showed that the metabolite sulforaphane-cysteine which displayed greater HDAC inhibitory effect than SFN at a concentration of 15 µM is the active form of SFN and other isothiocyanates. This observation was further confirmed by molecular studies which revealed a plausible interaction for sulforaphane-cysteine within the active site of the HDAC-like protein (see *Natural Product HDAC Inhibitor in the PDB*) ([@B145]). Moreover, 40% of the growth inhibition of xenografts of human PC-3 prostate cancer cell in mice by SFN was observed at a concentration of 15 µM, accompanied by as significant down-regulation of HDAC activity in the xenografts ([@B146]). Recently, SFN has been reported to selectively inhibit HDAC2 and 9 with IC~50~ values of 36 and 0.6 µM respectively ([@B31]). *In silico* studies confirmed that isothiocyanates can bind to allosteric active sites of HDAC based on their similar structural features with other HDAC inhibitors ([@B58]; [@B78]; [@B172]). However, isothiocyanates are known to react preferably with diverse thiol and amine (bio)nucleophiles ([@B87]), which strongly suggest non-specific and likely indirect effects on a given epigenetic target.

#### Bis(4-Hydroxybenzyl)sulfide {#s3_1_1_6}

Bis(4-hydroxybenzyl)sulfide (**18**) is a sulfur compound isolated from the root extract of the Chinese medicinal plant *Pleuropterus ciliinervis* ([@B202]). *In vitro*, it displayed inhibitory activity against HDAC in HeLa cells with an IC~50~ value of 1.43 µM ([@B202]). Besides, this compound inhibited also the growth of several cancer cells lines among which the prostate PC-3 and breast MDA-MB-231 cell line with IC~50~ values of 7.86 and 1.45 µM respectively ([@B202]). Like other organosulfur compounds, stability is a big issue that may affect the reproducibility of these findings.

### Cyclic Tetrapeptides ([**Figure 4**](#f4){ref-type="fig"}) {#s3_1_2}

#### Azumamide E {#s3_1_2_1}

The cyclic tetrapeptide azumamide E (**19**) was isolated from the marine sponge *Mycale izuensis* along with other azumamides (A, B, C, and D) ([@B149]). Structurally, azumamide E include four *D*-α-amino acids (*D*-Phe, *D*-Tyr, *D*-Ala, *D*-Val) and a unique *β*-amino acid assigned as the 13-membered macrocycle \[(*Z*)-(2*S*,3*R*)-3-amino-2-methyl-5-nonenedioc acid\] (known as Amnaa). Fusetani and co-workers reported that azumamide E possesses a strong inhibition of HDACs in K562 human leukemia cells, with an IC~50~ value of 0.064 µM ([@B149]). Another study reported that azumamide E selectively inhibited class I HDAC in HeLa nuclear extracts, particularly HDACs 1-3 with IC~50~ values of 0.05, 0.1, and 0.08 µM respectively ([@B129]). Docking studies showed that azumamide E inserts the Amnaa side chain into the active site of HDACs, where the carboxylic acid will chelate the Zn^2+^ in a bidentate fashion ([@B129]). Total synthesis of azumamide E revealed that switching of the carboxylic acid group to a hydroxamic acid leads to an increase in potency for HDAC inhibition ([@B234]). A subsequent synthesis of azumamide E by Villadsen et al., revealed that **19** is also a potent inhibitor of HDAC10 and 11 evidencing its lack of isoform specificity ([@B227]).

![Structures of cyclic tetrapeptides. The colors are representative of different parts shown in [**Figure 2**](#f2){ref-type="fig"}.](fphar-11-00992-g004){#f4}

#### Apicidins {#s3_1_2_2}

Apidicin (**20**) and apidicin A (**21**) are a family of natural products first isolated from the endophytic fungus *Fusarium pallidoroseum* ([@B195]). Structurally, all apicidins contain *N*-methoxy-*L*-tryptophan, except for apidicin A. Moreover, all apidicins contain *D*-pipecolinic acid, except for apidicin B (**22**) which contains *D*-proline. Furthermore, apidicin C (**23**) and F (**28**) contain *L*-valine and *L*-phenylalanine, respectively, while the other apidicins including apicidin D~1~ (**24**), D~2~ (**25**), D~3~ (**26**), and E (**27**) consist of *L*-isoleucine at the corresponding position. Another common feature of all the apidicins is the presence of (2*S*)-amino-8-oxo-decanoic acid (Aoda) or its derivative. These compounds displayed a high inhibitory activity of protozoal HDAC and in HeLa cell extracts in nanomolar range ([@B196]; [@B197]). A selective inhibition of class I HDAC2, 3, and 8 in nanomolar concentrations by apidicin A and D~1~ (**24**) has been reported as well as the inhibition of class IIa HDAC 4 and 7 in ovarian cancer cells ([@B96]; [@B2]). The binding of apicidin to the active site of HDAC is enabled through the insertion of the acetylated lysine mimic. Indeed, the carbonyl group can chelate the Zn^2+^ at the bottom of the active site precluding the binding of the natural substrate as demonstrated by the lack of activity of apicidin D~2~ (**25**) and D~3~ (**26**) ([@B34]; [@B196]). Apidicin inhibited the proliferation of diverse cancer cell lines through the induction of transcriptional activation of p21^WAFI/Cip1^ and gelsolin ([@B73]; [@B101]). The reversion of morphological changes of HeLa cells as well as hyperacetylation of histone H4 accompanied antiproliferative activity of apidicin on those cells ([@B73]). Apicidin-mediated growth inhibition of the promyelocytic leukemia cell line HL60 was also reported to be due to a transiently increased expression of Fas/Fas ligand. The latter resulted in activation of caspase-3 and 9 and execution of apoptotic cell death ([@B106]).

#### Helminthosporium carbonum *(HC) Toxin* {#s3_1_2_3}

HC-Toxin (**29**) is a cyclic tetrapeptide isolated from the fungal culture of *Helminthosporium carbonum* ([@B119]). The structure of HC-toxin consists of *D*-proline, *D*-alanine, *L*-alanine, and (2*S*)-amino-8-oxo-9,10-epoxydecanoic acid (Aoe). HC-Toxin is an inhibitor of HDAC in several organisms including plants, insects, and mammals ([@B230]). Its Aoe moiety has been reported to be relevant for HDAC inhibition as well as the α-keto epoxide moiety ([@B228]). Indeed, the latter binds covalently into the active site of HDAC through epoxide opening by nucleophilic residues of the active site ([@B228]). HC-toxin was reported to induce G0/G1-cell arrest and apoptosis in neuroblastoma (NB) cell lines and primary cell cultures in the nanomolar range ([@B40]). In other studies, HC-toxin displayed antiproliferative activity against intrahepatic cholangiocarcinoma (ICC) cells and breast cancers cells lines ([@B92]; [@B252]).

#### FR235222 {#s3_1_2_4}

FR235222 (**30**) was initially reported from the fermentation broth of the soil fungus *Acremonium* sp. No. 27082 ([@B141]). The structure of FR235222 consists of *L*-Phe and three unusual α-amino acids including (2*R*,4*S*)-4-*methylproline* (4-MePro), and (2*S*)-isovaline (iva), and (2*S*,9*R*)-2-amino-8-oxo-9-hydroxydecanoic acid (Aoh). This natural compound showed potent inhibition of partially purified HDAC fractions mammalian lymphoid cell lines (IC~50~ value of 17 nM) and selective immunosuppressive activity. Indeed, the authors found that FR235222 selectively inhibits both lymphocyte proliferation and lymphokine production; the target was identified as HDAC in T cells. The authors reported that FR235222 caused G1 cycle arrest accompanied by an increase of p21 and down-regulation of cyclin E, antiproliferative effects, and accumulation of acetylated histone H4. Another study, in which the prostate cancer cell line LNCaP was treated with FR235222 at a concentration of 0.5 µM, revealed that the increase in histone H4 acetylation is accompanied by caspase-3-dependent induction of apoptosis ([@B36]). Besides, the authors demonstrated that FR235222 can increase the level of the endogenous anti-inflammatory protein ANXA1 involved in apoptosis. It is worth mentioning that, the restoration of ANXA1 expression in the prostate cancer cell line LNCaP reduced cell viability and proliferative response and induced caspase-mediated apoptosis ([@B81]). FR235222, with an IC~50~ value of 60 nM, was also reported to inhibit HeLa cell HDACs and HDAC3 was identified as its main target in *Toxoplasma* tachyzoites ([@B242]; [@B17]).

AS1387392 (**31**), a synthetic analogue of FR235222, in which the MePro of FR235222 is replaced by proline, was also isolated from the same fungus *Acremonium* sp. This compound showed similar HDAC inhibitory effects as FR235222 with IC~50~ an value of 22 nM ([@B182]). AS1387392 also displayed potent inhibitory activity against splenocyte proliferation, with an IC~50~ value of 4.6 nM ([@B182]).

#### Chlamydocin {#s3_1_2_5}

Chlamydocin (**32**) was first isolated from the fungus *Diheterospora chlamydospria* and is a cyclic tetrapeptide containing 2-aminoisobutyric acid (Aib), *L*-phenylalanine, *D*-proline, and *L*-2-amino-8-oxo-9,10-epoxydecanoic acid ([@B33]). Chlamydocin exhibited cytotoxicity against mouse P-815 mastocytoma cells *in vitro* with a 10--100 times higher activity than clinical agents including actinomycin D, vinblastine, vincristine, amethopterin, and colchicine in the same assay ([@B207]; [@B229]). Chlamydocin has also been reported to inhibit the proliferation of diverse cancer cell lines with IC~50~ ranging from 0.36 to 45 nM. In the same study, it was reported that chlamydocin inhibits HDAC with an IC~50~ value of 1.3 nM and the antiproliferative activity was found to be accompanied by an increase in the accumulation of the acetylated histones H3 and H4, the induction of p21^Wafi/Cip1^, and cell cycle arrest in the G~2~/M phase ([@B184]). Chlamydocin selectively inhibited HDAC1 with an IC~50~ value of 0.15 nM ([@B58]). Chlamydocin may share a similar mode of action as the aforementioned epoxide-based HDAC inhibitors such as HC-Toxin.

The fungal culture *Tolypocladium* sp. produced a closely related compound 1-alaninechlamydocin (**33**), which displayed strong antiproliferative effects in a human pancreatic carcinoma cell line MIA PaCa-2 in a nanomolar range ([@B44]). Besides, 1-alaninechlamydocin also inhibited the growth of another human pancreatic carcinoma cell line (Panc-1) and the immortalized pancreatic duct cell line hTERT-HPNE at low-nanomolar concentration without induction of cytotoxicity in both cell lines at a concentration up to 10 µM. It was found that 1-alaninechlamydocin induces apoptosis and G2/M cell cycle arrest by inhibiting HDAC activity with an IC~50~ value of 6.4 nM ([@B44]).

#### Trapoxin (TPX) {#s3_1_2_6}

Trapoxin A (**34**) and B (**35**) are cyclotetrapeptides originally isolated from the fungal culture of *Helicoma ambiens* and caused the increase of highly acetylated core histones in diverse mammalian cell lines ([@B86]; [@B99]). Trapoxin A (**34**) (also known as trapoxin) induced cell differentiation, cell cycle arrest, and reversal of transformed cells morphology ([@B243]). Trapoxin (**34**) was first reported to be an irreversible HDAC inhibitors ([@B217]). However, Horinouchi and co-workers demonstrated later that trapoxin reversibly inhibits only HDAC6 through the ketone moiety. The latter undergoes a nucleophilic attack to form a zinc-bound tetrahedral gem-diolate without affecting the epoxide moiety ([@B58]). This mechanism is in contrast to other epoxyketone that are commonly thought to be irreversible HDAC inhibitors ([@B217]). In the same study, **34** displayed selective inhibition of HDAC1 and 6 with IC~50~ values of 0.82 and 524.0 nM respectively while **35** showed similar potency ([@B58]). Also, trapoxin B (**35**) was reported to be more potent than trichostatin A in the respective inhibition of H1299 and HCT116 cell proliferation ([@B174]). It has been reported that, trapoxin A (**34**) binds to the active site of HDAC8 through the same mode of action already known by its effect on HDAC6 ([@B165]).

#### Microsporin A {#s3_1_2_7}

Microsporin A (**36**) which is closely related to the trapoxins was produced by the fungus *Microsporum* cf. *gypseum* along with an analogue Microsporin B (**37**) ([@B68]). Both natural products harbor a nonproteinogenic moiety made of (2*S*)-amino-8-oxodecanoic acid (Aoda) and (2*S*)-amino-8-hydroxydecanoic acid respectively along with other units including *D*-pipecolinic, *L*-phenylalanine, and *L*-alanine ([@B68]). Microsporin A (**36**) showed potent *in vitro* cytotoxicity against human colon adenocarcinoma HCT-116 and a mean IC~50~ value of 2.7 µM in the National Cancer Institute's diverse 60-cell line panel. Microsporin A (**36**) in the same study showed greater *in vitro* inhibition against both a mixture of HDACs and HDAC8 than the reference antitumor agent HDAC inhibitor SAHA with IC~50~ values of 0.14 and 0.55 µM, respectively ([@B68]).

### Cyclic Depsipeptides ([**Figure 5**](#f5){ref-type="fig"}) {#s3_1_3}

#### Romidepsin {#s3_1_3_1}

The bicyclic depsipeptide romidepsin (**38**) was originally produced by *Chromobacterium violaceum* that displayed antitumor activity ([@B222]). This natural product was initially isolated under the name FR901228 and is now adays known as romidepsin or Istodax^R^ (trade name), or FK228 ([@B225]). In 2009, the prodrug romidepsin (**38**) was approved for the treatment of cutaneous and/or peripheral T-cell lymphoma by the US Food and Drug Administration (FDA) ([@B167]). The chemical structure of **38** consists of two valine units with opposite configurations, *D*-cysteine, (*Z*)-dehydrobutyrine, and (3*S*)-hydroxy-7-mercapo-4-heptenoic acid ([@B190]). Compound **38** acts as a potent and selective HDAC inhibitor of class I HDACs in particular HDAC1, 2, and 4 with IC~50~ values of 36, 47, and 510 nM respectively ([@B59]). This compound has an internal disulfide bond of **38** that is reduced in the presence of cellular glutathione to generate a sulfhydryl (thiol) moiety, which is the active form of Romidepsin behaving as a Zn^2+^ binding group in the active site.

![Structures of cyclic depsipeptides. The colors are representative of different parts shown in [**Figure 2**](#f2){ref-type="fig"}. The black color is representative of the product moiety.](fphar-11-00992-g005){#f5}

#### Largazole {#s3_1_3_2}

Largazole (**39**) was isolated through a bioassay-guided fractionation of the crude extract of the cyanobacterium *Symploca* sp. ([@B216]). Its structure consists of uncommon features including a thiazole ring linearly fused to a substituted (4*R*)-methylthiazoline and a (3*S*)-hydroxy-7-mercaptohept-4-enoic acid like in FK228. Largazole (**39**) selectively inhibited, at nanomolar concentration, the growth of the human epithelial cancer cells MDA-MB-231 in a dose-dependent manner. Indeed, non-transformed murine epithelial cells NmuMG remained unsusceptible to **39** in this study ([@B216]). The authors reported the same selectivity for transformed fibroblastic osteosarcoma U2OS cells (IC~50~ 55 nM) over nontransformed fibroblast NIH3T3 (IC~50~ 480 nM). It has been reported that **39** selectively inhibits class I HDAC1 over class II HDAC4 with IC~50~ values of 11.4 nM and 3 µM respectively ([@B205]). Largazole induced an increase of H3 and α-tubulin acetylation, and an up-regulation of p21^WAF1CIP1^ in NB4 cells ([@B205]). Increased acetylation of H3 and up-regulation of p21^WAF1XIP1^ was also observed in another study, in which **39** induced cell cycle arrest at G~1~ phase at nanomolar range concentration in HCT116 cells ([@B123]). Compound **39** is a prodrug that requires activation through hydrolysis to form the thiol **40** as the active form exhibiting high isozyme-selective HDAC inhibition activity ([@B79]).

#### Spiruchostatins {#s3_1_3_3}

Spiruchostatin A (**41**) and B (**42**), both sharing several structural features with romidepsin, were isolated from *Pseudomonas* sp. in 2001 ([@B127]). Another analogue, spiruschostatin C (**43**), was isolated from *Burkholderia thailandensis* ([@B127]; [@B103]). Spiruchostatin A--C (**41--43**) demonstrated selective inhibition of class I HDACs, in particular HDAC1, with low nanomolar IC~50~ values ([@B150]; [@B151]). Moreover, **41** was reported inhibiting 14 cancer cell lines at nanomolar range ([@B192]). In the latter study, it was found that **41** induces selective accumulation of acetylated histones in tumor tissues, p21^WAFI/Cip1^ expression and cell cycle arrest. Another study reported that a higher increase in the formation of intracellular reactive oxygen species accompanied induction of apoptosis in human lymphoma U937 cells by **41** and **42** ([@B173]).

Non Zinc-Binding Inhibitors ([**Figure 6**](#f6){ref-type="fig"}) {#s3_2}
-----------------------------------------------------------------

### Ursolic Acid {#s3_2_1}

The pentacyclic ursolic acid (**44**) can be found in fruits such as blueberries, apple peels, olive, and cranberries as well as in diverse herbs ([@B83]). Compound **44** was reported to inhibit the growth of HL60 cells resulting from an increase in the accumulation of acetylated histone H3 ([@B24]). The increased acetylation of H3 was found to be induced by the inhibition of HDAC 1, 3, 4, 5, and 6 ([@B24]). The binding of **44** to the active site of class I HDAC and HDAC7 isoforms has been recently confirmed through docking studies ([@B85]). Moreover, the same study showed **44** fulfills oral druggability of Lipinski rule five.

![Structures of the non Zinc-binding HDACs.](fphar-11-00992-g006){#f6}

### Epicocconigrones {#s3_2_2}

Epicocconigrones A (**45**) and B (**46**) are polyketides isolated from an endophytic fungus identified as *Epicoccum nigrun* in 2013 ([@B46]). Compound **45** displayed strong inhibition of HDAC with an IC~50~ value of 9.8 µM ([@B46]). *In vitro* test of **45** showed that this compound inhibits several HDACs (1, 2, 3, 8, 6, 10, and 11) with IC~50~ values between 1.6 and 12.9 µM. It is worth to mention that **45**, selectively inhibited HDAC8 with higher potency in comparison to the reference compound SAHA in the same study. Compound **45** also inhibited proliferation of the human lymphoma cell line RAJI by 50% at a concentration of 5 µM after 72 h of treatment. Moreover, 32% of the U937 cell line were also inhibited at the same concentration ([@B46]).

### Curcumin {#s3_2_3}

The polyphenol curcumin (**2**), as mentioned earlier, was isolated from the rhizome *Curcuma longa* ([@B201]). Curcumin (**2**) is known to possess HDAC inhibitory activity in different cancer cell lines ([@B200]). Indeed, induction by curcumin of cell cycle arrest at G2/M phase, apoptosis, and increase in tubulin acetylation in medulloblastoma cells, through the inhibition of HDAC, in particular HDAC4 was reported ([@B113]). It has been reported that **2** may be of considerable value in synergistic therapy of cancer in a manner that the drug dose level could be strongly minimized to reduce the associated toxicity ([@B176]). Indeed, **2** combined with other HDAC inhibitors such as vorinostat resulted in a marked enhancement of the antiproliferative activity of the associated drug, and sensitization to apoptosis ([@B64]). A similar observation was made when **2** was combined with cyclophosphamide and paclitaxel ([@B176]). Nevertheless, curcumin is known to show pan-activities, which is why any reported specificity needs to be seen with caution.

### *n*-Butyric Acid {#s3_2_4}

*n*-Butyric acid (**47**) is a short-chain fatty acid reported as metabolite of *Staphylococcus epidermidis*, a skin probiotic bacterium ([@B32]; [@B220]). *n*-butyric acid has been reported to inhibit HDAC, DNA synthesis, and cell growth in colon tumor cell lines ([@B8]; [@B247]; [@B220]). Its poor pharmacological properties are due to a rapid metabolism. Along with the multigram doses required to achieve therapeutic concentrations *in vivo*, they precluded its use in cancer therapy and other medical disorder ([@B139]; [@B208]). To overcome this limitation, butyric acid prodrugs have been synthesized including pivaloylomethyl butyrate (AN-9) (**48**) and butyroyloxymethyl butyrate (AN-1) (**49**), which showed antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas ([@B48]). However, these prodrugs did not succeed as viable drugs ([@B208]). Interestingly, the arginine salt of butyrate gave successful results in clinical studies and is used for the treatment of diseases such as thalassemia and sickle-cell disease ([@B208]). Other short-chain fatty acids such as 4-phenylbutyrate (**50**), 2,2-dimethlbutyric acid (**51**), and valproic acid (**52**) have been synthesized and also displayed inhibition of HDAC ([@B208]). Valproic acid (**52**) is currently used in the treatment of epilepsy ([@B62]). Thus, butyrate-based epigenetic compounds represent a promising route for the development of new HDADi.

### Aceroside VIII {#s3_2_5}

Aceroside VIII (**53**) is a diarylheptanoid isolated from the Japanese white birch *Betula platyphylla*. This compound weakly but selectively inhibited the activity of HDAC6 in HT29 CRC cells ([@B180]). However, combination of this compound with the well-known selective HDAC6 inhibitor γ-lactame A452 led to a significant increase of the levels of acetylated α-tubulin. Furthermore, the treatment of HT29 CRC cells with 10 µM aceroside VIII associated with 0.1 µM A452 led to a significant decrease of cell growth up to 84% ([@B180]). The same study showed that cell death caused by aceroside is partly dependent on caspase activation. This study highlighted a synergistic effect of natural products and selective HDAC6 inhibitors.

Molecular Modeling and Docking as a Tool for a Mode of Action Prediction of Natural Product DNMTs and HDACs Inhibitors {#s4}
======================================================================================================================

Molecular docking is a computational method employed for understanding, the interaction between a small molecule (e.g. a potential drug) and its macromolecular target, e.g. a protein or receptor. Docking simulations are often used to elucidate the key binding interactions and binding modes of small molecules and their drug targets ([@B95]). Scoring functions are mathematical/statistical methods implemented in docking algorithms for quantifying the interactions, hence the putative binding of a drug molecule to its target ([@B29]). When properly trained, a scoring function could be used as a criterion for selecting a subset of (best-scoring) ligands or small molecules, which have been stored in electronic databases (often several thousands or even millions). During a virtual screening experiment via docking, a large electronic database of ligands is docked into the binding site of a protein and putative binding is characterized using a scoring method. For each ligand, several conformers are stored as \"docking poses\" and the top-scoring poses are chosen as potential binders. This selected subset of compounds (called docking \"hits\") are then tested biologically. Thus, the number of compounds to be tested is drastically reduced, hence cutting down the cost of identification of a lead compound.

Structure-based molecular modeling (e.g. molecular docking, molecular dynamics, structure-based quantitative structure-activity relations) and ligand-based modeling (e.g. pharmacophore modeling, similarity searching) have assisted the identification of novel natural product inhibitors and modulators of DNMTs and HDACs and in explaining their inhibitory effect. Some of these results have been summarized in recent reviews ([@B132]; [@B181]).

Interactions of Natural Compounds Within the Binding Site of DNMT1 {#s4_1}
------------------------------------------------------------------

The anthraquinone derivative Nanaomycin A (**6**), from the National Cancer Institute (NCI)/Developmental Therapeutics Program Open Chemical Repository screening program (<http://dtp.cancer.gov>), displayed potent antiproliferative effects on HCT116, A549, and HL60 cell lines as mentioned earlier in this review ([@B104]). A study on the identification of DNMT1 inhibitors through a virtual screening showed that **6** induces antiproliferative effects in three different tumor cell lines ([@B23]). Furthermore, biochemical *in vitro* assay using DNMT1 or DNMT3b showed that nanaomycin A selectively inhibits DNMT3b. A docking study of nanaomycin A towards a homology model of the catalytic site of DNMT3b was conducted in order to rationalize the biochemical activity at the molecular level ([@B104]). Indeed, docking studies confirmed that nanaomycin A binds in the active site of DNMT3b in which its carboxylic acid is capable of forming hydrogen bonds with the side chain of arginine residues. Moreover, its carbonyl oxygen atom and adjacent hydroxyl group were predicted to form an extensive hydrogen bond network with the side chain of two arginine residues. Besides, the side chain of a glutamic acid residue forms a hydrogen bond with the hydroxyl. Furthermore, a possible explanation of the selectivity of nanaomycin A for DNMT3b was suggested. Indeed, docking studies of nanaomycin A with a previously validated homology model for the catalytic site of human DNMT1 did not shown similar H-bonds with the equivalent glutamic acid and arginine residues ([@B194]). Thus, the anticancer effects of nanaomycin A could be attributed to its ability to selectively inhibit DNMT3b. Thus, the anthracycline group of nanaomycin A represents a valuable scaffold for the development of future selective DNMT isoform inhibitors. However, some lasting cardiotoxicity may prevent its clinical use. It is worth to mention that nanaomycin A is the first non-SAH (*S*-adenosylhomocysteine) DNMT3b-selective compound.

Based on the anticancer activity of the isoflavone genistein toward MDA-MB-231 human breast cancer cells and MCF-7, associated with the resulting decrease in the level of global methylation, a docking study, similar to the aforementioned nanaomycin A, was performed. Indeed, molecular modeling of the interaction between genistein and the DNMT1 binding site, as shown in [**Figure 7**](#f7){ref-type="fig"}, revealed potential H-bond interactions ([@B238]). This study demonstrated that genistein might inhibit the binding of hemimethylated DNA, competitively to the catalytic domain of DNMT1. Moreover, the authors also demonstrated that genistein has a demetylation effect in the region of multiple tumor suppressor genes (TSG) including Adenomatous polyposis coli (APC), ataxia telangiectasia mutated (ATM), phosphatase and tensin homolog (PTEN), and increased the mRNA expression of these genes. It is worth to mention that, silencing of the expression of TSGs in cancer cells is mainly due to hypermethylation of CpG islands in the promoter region ([@B238]). These results suggested that genistein could increase the expression of certain TSGs in human breast cancer cells by reducing the activity of DNMTs and mRNA expression of DNMT1. Thus, genistein or its structural analogs could be potentially used as demethylation agents.

![H-bond interactions between Genistein and binding site amino acid residues in the DNMT1 cavity. H-bond between genistein and DNMT1 are shown (distance \<3.2 Å) as red dotted lines that include the names of the residues and distances (Reproduced with permission).](fphar-11-00992-g007){#f7}

Similarly, molecular docking has been used to illustrate why the phenolic derivative curcumin (**2**) inhibits the enzymatic activity of an analogue of DNMT1 (M. SssI) at the lower nM range, meanwhile a close natural analogue, hexahydrocurcumin (**54**), showed no inhibition of the same enzyme up to 100 μM ([@B122]). This finding could be explained by docking of curcumin and its tetrahydro analogue towards the catalytic domain of DNMT1. Since it was suggested experimentally that curcumin blocks the catalytic thiolate of Cys1226 of DNMT1 covalently to exert its inhibitory effect, docking validation showed the absence of such interactions in docking pose with the other docked curcumin analogues, including demethoxycurcumin (**55**), bisdemethoxycurcumin (**56**), tetrahydrocurcumin (**57**) ([**Figure 8**](#f8){ref-type="fig"}, [@B122]). Compounds **2**, **55**, and **56** showed similar inhibitory effects, indicating that either of bis-α,β-unsaturated ketones is required for the observation of the activity. However, as mentioned earlier, the bioactivity of curcumin should be analyzed with care.

![Modeling docking poses towards the homology model of showing the interaction of curcumin (2) and its two analogs (50--51) **(A)** and tetrahydrocurcumin (52, **B**) within the catalytic domain of DNMT1. The catalytic Cys1126, and anchoring Glu1668, Arg1312 are shown in the catalytic domain, (Reproduced with permission).](fphar-11-00992-g008){#f8}

Discovery of Novel DNMT Inhibitors by Docking-Based Virtual Screening {#s4_2}
---------------------------------------------------------------------

Several isoforms of DNMTs occur in mammals, e.g. DNMT1, DNMT3a, and DNMT3b as mentioned earlier in this review ([@B25]). These are attractive targets in cancer chemotherapy and several crystal structures are available in the protein databank ([@B15]) for structure-based virtual screening projects (e.g. PDB ID: 4DA4) ([@B204]). Several successful virtual screening campaigns *via* docking have been conducted for the discovery of DNA methyltransferase inhibitors ([@B104]; [@B134]; [@B133]; [@B25]). These include, for example, 44 natural germacrolides docked against the homology model of the human DNMT1 ([@B122]), and the lead-like subset of \~89,425 natural products from the ZINC database ([@B84]) which were docked against the homology model of the human DNMT1 ([@B134]). Indeed, from the docking-based screening performed by Liu and co-workers, it was observed that γ-methylactone compounds could be effective DNMT inhibitors. Moreover, the same study resulted in the discovery of parthenolide and curcumin mentioned earlier in this review. This result was confirmed by Yoo and coworkers who demonstrated that the binding models of compounds such as curcumin and parthenolide suggest that these natural products are covalent blockers of the catalytic site of DNMT ([@B241]). Thus, compounds such as parthenolide are potential blockers of DNMT1.

Natural Product HDAC Inhibitor in the PDB {#s4_3}
-----------------------------------------

Based on the evidence of HDAC inhibitory effects along with tumor-suppressing activities of SFN (**8**), [@B145] carried out a molecular modeling study of the SFN-Cys HDAC binding site on the HDAC crystal structure. It was shown that the buried cysteine amino group is positioned to make a single H-bond with His132 when **8** was made to interact with this binding site ([@B145]). The same study reported that a combination of SFN (**8**) with trichostain A (**13**) led to an increase in the inhibition of the HDAC activity. It is worth to mention that **8** is metabolized into its major active form sulforaphane-cystein. Indeed, studies with SFN and media treated from SFN-treated cells indicated that the parent compound was not responsible for the HDAC inhibition activity, and this was proven through the use of glutathione S-transferase that blocked the first step in the metabolism of SFN ([@B145]). Therefore, SFN may be an effective stand alone chemotherapeutic agent or work in synergy with other HDAC inhibitors. However, the lack of isoform selectivity inhibition may limit its potential clinical use.

Based on the known inhibitory activity of trichostatin A (TSA) (**13**), [@B54] carried out a molecular modeling study of this compound to establish the mechanism of HDAC inhibition ([@B54]). This study showed that the binding of TSA proceeds by the insertion of its long aliphatic chain into the HDLP pocket, thus making multiple tube-like contacts to the hydrophobic portion of the pocket. Furthermore, it was revealed that the hydroxamic acid group of TSA coordinates the active-site zinc in a bidentate fashion using its carbonyl and hydroxyl group. It is worth to mention that other natural HDAC inhibitors such as HC-toxin (**29**) and trapoxin (**34**) mentioned earlier in this review, contain groups that are analogous to the active-site/zinc-binding groups and the cap aliphatic chain of TSA. However, they have an epoxyketone group instead of a hydroxamic acid group. It has been suggested that the epoxy group may crosslink to an active site nucleophile ([@B243]). Furthermore, interaction of their ketone group with polar residues and possibly the zinc, at the bottom of the active-site pocket might be possible ([@B54]). Indeed, the reduction of the carbonyl to a hydroxyl group, or its elimination, that led to a high decrease in the activity of **29**, supported this assumption ([@B193]). This mode of action could be assumed to be identical for other HDAC inhibitors including chlamydocin (**32**), 1-alaninechlamydocin (**32**). Besides, the authors suggested that the larger size of the macrocycle (cap group) of **34** and **29** compared to that of **13** could allow more extensive contacts at the rim of the pocket and in the shallow grooves surrounding the pocket entrance.

HDAC Inhibitors Inspired From the Natural Product Psammaplin A (PsA) {#s4_4}
--------------------------------------------------------------------

Inspired by the NP PsA (**15**), [@B13] designed a new set of picolinamide-based histone deacetylase inhibitors, i.e. designing a focused library, which is based on the PsA core ([@B13]). Based on the HDAC inhibitory and anti-tumor ([@B61]) activities of this marine metabolite, the authors proceeded by probing the features of this molecule, which are responsible for its activity ([@B12]). In searching for a molecular replacement for the oxime unit of psammaplin A, Baud and coworkers were able to discover a new set easily synthesizable, isoform-selective, fragment-sized, and highly ligand efficient *N*-2-(thioethyl)picolinamide HDAC inhibitors bearing a chloropyridine motif, with low-nanomolar potencies ([@B13]). The synthesized compounds selectively inhibited HDAC1 with low-nanomolar potencies. Because selective HDAC1 inhibition has been suggested to be an effective anticancer strategy, this study showed that compounds with the chloropyridine motif will be a valuable design criterion for lead compound development of new and chemical probes that target HDAC1.

Further molecular modeling of the compound PsA and its most potent designed analogs as cytotoxic agent that act by histone deacetylase inhibition ([@B235]) was conducted against the HDAC1 binding site (PDB ID: 4BKX) ([@B138]). A comparison of the binding interactions was carried out, for example, of the synthetic analogue; (2*E*,2′*E*)-*N*,*N*′- (disulfanediyl*bis*(ethane-2,1-diyl))*bis*(2-(hydroxyimino)-3-(2,4-dichlorophenyl)propanamide, which showed better HDAC inhibitory activity than PsA and comparable antiproliferative activity with psammaplin A (**15**) against all four tested cancer cells ([@B235]). [**Figure 9**](#f9){ref-type="fig"} shows that psammaplin A binds to HDAC1, forming key interactions with the protein in several areas. For example, the thiol group in PsA chelates the Zn^2+^ ion, while the oxime group forms an H-bond with Asp99 bridged by a water molecule. On the other hand, the 3-bromo-4-hydroxy phenyl group in PsA forms a few hydrophobic contacts to His178, Tyr204, and Phe205 around the surface recognition motif, while the hydroxyl group is optically attached to the *para*-position of benzene. This enhances interaction with Glu203 at the entrance to the active site tunnel ([**Figure 9**](#f9){ref-type="fig"}). Besides, it was observed from molecular dynamics studies that the non-covalent interactions between the inhibitor and target protein were quite stable through 2.5 ns. The more potent synthetic analogue of this NP (shown in [**Figure 9B**](#f9){ref-type="fig"}) shared a similar binding mode as PsA, with similar and stable interactions. However, as mentioned earlier, the physiologic instability of PsA has precluded further clinical investigations.

![3D view of the docking pose of reduced PsA **(A)** and its synthetic analogue **(B)** to HDAC1 (PDB ID: 4BKX). The ligands are shown in orange and green, respectively. Important parts of the enzyme for interaction are shown in magenta sticks, while Zn^2+^ ion is shown as a light-yellow sphere (Reproduced with permission).](fphar-11-00992-g009){#f9}

Conclusion {#s5}
==========

Despite intensive research efforts, cancer is yet one of the primary global causes of death. Although numerous potent anti-cancer drugs have been developed in recent decades, there is still a huge need for specific agents with low side effects ([@B18]). DNA methylation and histone acetylation are important physiological mechanisms that maintain genome integrity. Altered DNA methylation and/or histone acetylation patterns have consistently been documented as the earliest molecular changes occurring upon tumor establishment. Since the presence of HDACs are important in both the development and progression of cancer, addressing the related epigenetic processes with HDAC inhibitors (HDACi) is a promising starting point for developing new and potent anticancer drugs ([@B117]). HDAC inhibitors have already proven their fundamental efficacy against cancer in preclinical and clinical studies, which has led to the FDA approval of vorinostat (SAHA), romidepsin (FK288), panobinostat (LBH589), and belinostat (PXD101) for cancer therapy ([@B153]; [@B211]; [@B137]). Besides, a double-digit number of other HDAC inhibitors are currently under investigation in Phase II or III trials ([@B211]). Nevertheless, it should be noted that many HDAC inhibitors fail in clinical development due to lack of efficacy or too many side effects ([@B199]). Another major drawback is the fact that the majority of the already established HDAC inhibitors are only approved for the treatment of T-cell lymphomas, due to insufficient efficacy against solid tumors ([@B199]). Consequently, the identification of new HDAC inhibitors that are both potent and specific is of great importance to adequately address the pathophysiological importance of epigenetic mechanisms in modern cancer therapy. Many compounds are made chemically in academia and industry for the development of new HDACi. However, nature also offers an almost inexhaustible pool of new bioactive substances, often exhibiting novel and unexpected chemical scaffolds ([@B76]; [@B26]). Countless drugs based on natural products are impressive proof of the healing power hidden in nature ([@B41]). For these reasons, it seems highly advisable to screen newly discovered natural products for HDAC inhibitory activity to identify new and superior lead compounds for the development of a new generation of HDAC inhibitors. Moreover, emerging reports show that intelligently designed combination therapies with common cytostatic drugs can synergistically increase the efficacy of the inhibitors ([@B211]).

Many of the points discussed for HDACi apply in a similar or even the same way to DNA methyltransferase inhibitors (DNMTIs). For example, DNMTIs are most effective in hematological diseases such as myelodysplastic syndromes, whereas treatment success in solid tumors is limited ([@B69]). Similar to HDACi, the aim is therefore to use wisely designed combination treatments to synergistically enhance the effect of well-established anti-cancer drugs through HDACi ([@B66]). This approach is certainly functional, as shown by the combination with oxaliplatin or doxorubicin ([@B56]; [@B226]). One problem associated with the clinical use of classical DNMTIs is that they often exhibit mutagenic effects, such as 5-azacytidine or zebularine ([@B7]; [@B111]). Here, natural product-based DNMTIs such as epigallocatechin-3-gallate appear to be more advantageous, since the latter is not incorporated into the DNA, but binds directly to the catalytic region of DNMTs ([@B52]).

Natural products endowed with DNMTs and HDACs inhibition functions were reviewed in this article. Indeed, a wide range of natural compounds from plants, microorganisms, and marine sponges was presented and their potential to inhibit DNMTs and HDACs discussed. Furthermore, this study showed that compounds possessing a strong zinc-binding group are more promising HDAC inhibitors even though the presence of the latter is not a prerequisite for HDAC inhibition. Molecular modeling and docking increasingly shows to be a powerful tool for studying the interactions between the drug target and its potential inhibitors, paving the way towards the further development of novel HDAC and DNMT inhibitors as anti-tumor agents which could be natural product-inspired. However, most of the natural products presented showed an indirect effect and lack isoform selectivity, which may limit their development into clinical use. The capability to selectively inhibit single HDAC or DNMT isoforms currently represents a major challenge in the design of HDAC and DNMT inhibitors. This approach could represent an opportunity to derive improved agents which could target specific types of cancer. It is worth to mention that, combination of HDACs or DNMTs inhibitors with anti-EZH2 could increase their efficacy without overlapping toxicity ([@B186]). This implies the identification of natural products that could target other epigenetic regulatory enzymes which is beyond the scope of this review.

HDACi are important for innate defense function, macrophage differentiation, and polarization ([@B72]). Indeed, treatment of B16/F10 murine melanoma cells by the natural HDACi romidepsin showed that HDACi are promising agents in the human melanoma immunotherapy pretreatment ([@B143]). A study by [@B19] showed the importance of TsA in the regulation of macrophage differentiation and elongation ([@B19]). Another study also highlighted that TsA treatment inhibits inflammatory cytokine secretion and improves both CD1d and class II MHC-mediated antigen presentation. Thus, this treatment may enhance the suppression of antitumor NK T cell responses ([@B218]). The same study showed that the restoration of antitumor responses to mantle cell lymphoma could be improved by treatment with HDACi. Based on these observations and despite the need of additional preclinical data to access the efficacy and toxicity of HDACi, several clinical investigations have started by associating HDACi with immunotherapeutics for patients with advanced prostate, renal, or urothelial cell carcinoma ([@B130]). Another study suggested that SAHA might improve the activity of the immunotherapeutic avelumab in both tumor and NK cells ([@B77]). It is worth to mention that SAHA possesses also a hydroxamic acid function such as trichostatin A indicating that a possible derivatization of the latter could improve its efficacy. Thus, these studies suggest that combination of natural HDAC inhibitors with immunotherapeutics could improve the treatment of cancer. However, preclinical studies to access the efficacy and toxicity of this combination are still needed. A particular interest should be given on class I-specific HDACi, which are believed to provide a promising future in the cancer treatment ([@B130]). Indeed, combination of natural selective HDAC inhibitors might increase the anticancer drug efficacy as demonstrated in the case of the natural HDAC6-selective inhibitor aceroside VIII ([@B180]).

However, the multitarget effects of natural products is a serious limitation of their use in the area of epigenetic drugs. Thus, chemical derivatization and molecular studies could improve their effects for a better understanding of their mechanism of action. On the other hand, the multi-target property of natural products could be utilized for the treatment of diseases including cancer, Alzheimer's disease, and diabetic cardiomyopathy. Indeed, promising multi-target molecules have been studied for the aforementioned diseases ([@B144]; [@B10]; [@B94]). In addition, only few virtual screenings studies have been performed yet and their increase will provide hope for the discovery of potential DNMT and HDAC inhibitors. Nonetheless, the structures presented in this review offer the well-founded basis that screening and chemical modifications of natural products will in future provide not only leads to the identification of more specific inhibitors with fewer side effects, but also important features for the elucidation of HDAC and DNMT function for cancer treatment.
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